MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; William Origer, MD; Stacy Ramirez, PharmD; Jim Rickards, MD, MBA; James Slater, PharmD; Cathy Zehrung, RPh

Members Present by Phone: Kelley Burnett, DO

Staff Present: Roger Citron, RPh; Richard Holsapple, RPh; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Renae Wentz, MD; Dee Weston; Jonnaliz Corbett; Trevor Douglass, DC, MPH

Staff Present by Phone: N/A

Audience: *Margaret Olmon, AbbVie; *Elise Conlee, Greenwich Biosciences; *Paul Williams, Genentech; *Stuart O’Broonth, Gilead; Paul Bonham, Avexis; *Valerie Ng, Invidior; Georgette Dzwilewski, Invidior, Tim McFerrero; Don Noper, Dova; Keri Smith, ViiV; Heather Hays, Array Biopharma; *Chris Conner, BMS; Camille Kerr, Amgen; Alex Bithy, Bioverativ; Katie Peters, Oregon State University; Jeana Colabianchi, Sunovio; *Ryan Flynn, Dova; Bobbi Su Duim, BMS; *Sylvia Churchill, Amgen; Laura Jeffcoat; Danielle Shannon, WVP Health; Meridith Bradshaw; *Chioma Ezenduka, UCB; *Ryan Fowler, Pfizer; Andrew Yu, Novartis; Mark Pledge, Novartis; Amy Burns, AllCare CCO; Lisa Boyle, WVP Health, *Colin Roberts, OHSU

*Provided public testimony

Written testimony provided: Posted to OSU Website
I. CALL TO ORDER

A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff.
B. No new conflicts of interest were declared.
C. Election of Chair & Vice Chair

   Tracy Klein was nominated as chair.
   **ACTION: Motion to approve, 2nd, all in favor**

   Caryn Mickelson was nominated as vice chair.
   **ACTION: Motion to approve, 2nd, all in favor**

D. Approval of agenda and November 2018 minutes presented by Mr. Citron.
   **ACTION: Motion to approve, 2nd, all in favor**

E. Department Update: Dee Weston reported she did not have any updates on behalf of the OHA
F. Legislative Update: Trevor Douglass said the OHA was tracking a number of bills, but nothing to report at this time and he will arrange for an update at the March P&T meeting

II. CONSENT AGENDA TOPICS

A. P&T Operating Procedures
B. P&T Methods
C. OHA onboarded the new committee members and updated the operating procedures and methods. The changes are available in the [packet beginning on page 8](#) and [Posted to OSU Website](#).
D. Fibromyalgia Indication Review
E. Erythropoiesis Stimulating Agents Literature Scan

III. DUR OLD BUSINESS

A. Hepatitis C Direct Acting Antivirals

IV. DUR NEW BUSINESS

A. Substance Use Disorder Class Update/Drug Use Evaluation
   Dr. Moretz and Dr. Servid presented the proposal to:
   - Make lofexidine non-preferred on the Preferred Drug List (PDL) and implement Prior Authorization (PA) criteria to ensure appropriate utilization.
   - Add extended release subcutaneous buprenorphine injection (Sublocade) to PA criteria for buprenorphine and buprenorphine/naxolone products (Appendix 6).
   - No PA or PDL changes recommended based on utilization.
   - Evaluate comparative costs in executive session.
ACTION: revise the PA criteria to document concomitant naloxone use when available and upon approval of the PA. Include messaging recommending concomitant naloxone prescribing if needed. The committee also requested staff evaluate MAT continuation over a longer period >6 months. Collect, evaluate co-prescribing information with naloxone and evaluate further non-pharmacological therapy.

The committee recommended a newsletter regarding best practices/pearls for MAT, including new therapies and recommendations for co-prescribing naloxone and psychosocial support.

Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST NEW BUSINESS

A. Antiepileptics Class Update
Dr. Moretz presented the proposal to:
- Implement PA criteria to ensure medically appropriate utilization of cannabidiol and stiripentol.
- Revise clobazam criteria to include Dravet Syndrome as an indication (based on 2012 NICE guidance) and add renewal criteria.
- Review comparative drug costs in the executive session.

ACTION: amended to reorder #4 and #5 in cannabidiol PA criteria and add a question confirming concurrent use of other antiepileptic therapy to cannabidiol initial and renewal criteria.

The committee asked staff to evaluate use of solution formulations and whether they are actually needed for the patients they are prescribed.

Motion to approve, 2nd, all in favor

B. Drugs for Thrombocytopenia Class Review
Dr. Sentena presented the proposal to:
- Add the Thrombocytopenia Class to the PMPDP.
- Implement proposed PA criteria for non-preferred drugs.
- Evaluate costs in executive session to determine PDL status.

ACTION: amend proposed PA criteria to: confirm presence of chronic liver disease prior to approval in question #5; revise approval duration to be 3 months with initial approval and 12 months upon renewal; and add evaluation of LFTs. The committee also asked to monitor requests to ensure PA is not causing undue delay in surgical procedures.

Motion to approve, 2nd, all in favor
C. Influenza Antivirals Class Update  
Dr. Servid presented the proposal to:  
- Make baloxavir marboxil non-preferred and subject to prior authorization criteria due to lack of available evidence in high risk patients and concerns with potential resistance.  
- Review comparative costs in executive session.

**ACTION:** Motion to approve, 2nd, all in favor

D. Biologics for Autoimmune Conditions Class Update  
Dr. Moretz presented the proposal to:  
- Modify PA criteria reflect updated indications and age ranges for specific biologics.  
- Modify PA criteria to include tildrakizumab for use in moderate-to-severe plaque psoriasis for adults.  
- Modify PA criteria to include baricitinib for use in moderate-to-severe rheumatoid arthritis for adults.  
- Evaluate comparative costs in executive session.

**ACTION:** for questions which require DMARD step therapy (e.g.#13), add language specifying that the patient has tried/failed “or had inadequate response” to these treatments and amend criteria to support continued therapy with DMARDs in combination with biologics where appropriate. The committee also requested staff perform a DUE of biologic utilization.

**Motion to approve, 2nd, all in favor**

E. Colony Stimulating Factors Class Update  
Dr. Sentena presented the proposal to:  
- Make no changes to the PMPDP based on clinical evidence.  
- Evaluate comparative drug costs in executive session.

**ACTION:** Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

**Members Present:** Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; William Origer, MD; Stacy Ramirz, PharmD; Jim Rickards, MD, MBA; James Slater, PharmD; Cathy Zehrung, RPh

**Members Present by Phone:** Kelley Burnett, DO; James Slater, PharmD

**Staff Present:** Roger Citron, RPh; Richard Holsapple, RPh; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Renae Wentz, MD; Dee Weston; Jonnaliz Corbett; Trevor Douglass, DC, MPH

**Staff Present by Phone:** N/A

VII. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session
A. Hepatitis C Direct Acting Antivirals
   **Recommendation:** update the recommendation made at the November P&T meeting, which was to optimize Mavyret use when fibrosis restrictions are removed, and instead to continue to prefer glecaprevir/pibrentasvir (Mavyret™), sofosbuvir/velpatasivir (both brand Epclusa® and the authorized generic), and elbasvir/grazoprevir (Zepatier®) as recommended regimens for hepatitis C for their respective FDA-approved indications.

B. Erythropoiesis Stimulating Agents Literature Scan
   **Recommendation:** no changes to the PMPDP

C. Substance Use Disorder Class
   **Recommendation:** no changes to the PMPDP

D. Antiepileptics Class Update
   **Recommendation:** no changes to the PMPDP

E. Thrombocytopenia Class Review
   **Recommendation:** make eltrombopag (Promacta®) and romiplostim (Nplate™) preferred and fostamatinib (Tavalisse™), lusutrombopag (Mulpleta®) and avatromopag (Doptelet®) non-preferred on the PMPDP.

F. Influenza Class
   **Recommendation:** no changes to the PMPDP

G. Biologics for Autoimmune Conditions Class
   **Recommendation:** maintain tildrakizumab-asnm (Ilumya™) and baricitinib (Olumiant®) as non-preferred on the PMPDP and no other changes.

H. Colony Stimulating Factors Class Update
   **Recommendation:** make filgrastim-sndz (Zarxio®) non-preferred on PMPDP.

**ACTION:** Motion to approve items, 2nd, all in favor

---

**VIII. ADJOURN**